Should I buy Doximity (DOCS) stock or is it too late?

Doximity · Health Care · price $31

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Truist Securities — 65% of its targets hit on this sector (110 calls tested). It aims for $24 (-21 %), call made on August 14, 2026, maturing on August 14, 2027 (61 d ago).

The 3 reliable analysts $24-21 %

The 14 other firms $26.50-13 %

How to read it: the 3 reliable firms are not filtered by optimism — 1 aim above the price, 2 below, hence their $24 median. “The 14 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Doximity

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Canaccord Genuity	29 %	+8.4 %	7	$30 -2%
JP Morgan	60 %	-10.1 %	5	$31 +1%
Needham	18 %	-25.0 %	11	$27 -12%
Baird	33 %	-26.2 %	6	$18 -41%
Keybanc	0 %	-40.9 %	5	$30 -2%
Morgan Stanley	29 %	-56.1 %	7	$35 +15%
Raymond James	20 %	-36.6 %	10	—

In short — Should you invest in Doximity? Is it too late, still worth it? Analysts are split (26% buy, median target $26, i.e. -15%), and the most reliable on DOCS targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

The most reliable firm on DOCS, JP Morgan (60% hit rate, 5 scored calls), targets $31 (call made on August 7, 2026, maturing on August 7, 2027) (+1%) in its most recent call, and $40 (call made on February 6, 2026, maturing on February 6, 2027) (+31%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 19 ratings, 12 are neutral and 2 are sells.
Limited upside: the median target is only -15% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on DOCS

Median target $26 (-15%) · 19 ratings · Hold consensus

Strong Buy00%

Buy526%

Hold1263%

Sell211%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Doximity now?

We won't decide for you. The facts: 26% of analysts rate it a buy, median target $26 (-15%), and JP Morgan (most reliable on DOCS, 60%) targets $31. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Doximity?

The stated upside is small: the median target ($26) sits just -15% from the price ($31) (most reliable on DOCS: JP Morgan, 60%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Doximity still worth investing in?

It depends on the gap between the price ($31) and its estimated value: analysts target $26 on median (-15%), with 26% buys (most reliable on DOCS: JP Morgan, 60%). Cross-check with their real reliability on DOCS and the cautions above. Information, not advice.

What's the main risk in buying DOCS?

The consensus is not unanimous: of 19 ratings, 12 are neutral and 2 are sells.

→ Go deeper: the full Doximity profile (consensus, analyst reliability, price target, performance).